Shukra Pharmaceuticals Inks MoU with Borns Medical Robotics to Introduce AI-powered Surgical Robots in India

The collaboration integrates AI with digital surgery workflows for improving clinical efficiency and reducing variability in surgical outcomes.

Shukra Pharmaceuticals has entered into a Memorandum of Understanding with US-based Borns Medical Robotics.

The partnership seeks to introduce and commercialize AI-powered surgical robotic systems in India and select South Asian markets, marking its entry into the fast-growing medical robotics space.

The MoU outlines a framework under which the two companies intend to introduce, promote and commercialise medical robotics solutions across India as well as Nepal, Bangladesh, Sri Lanka, Maldives and Bhutan, subject to regulatory approvals.

The proposed initiative will be executed through Shukra Robotics, a wholly owned subsidiary of Shukra Pharmaceuticals.

AI-powered medical robotics systems are increasingly being adopted globally to support surgeons with enhanced visualisation, stability and workflow standardisation, particularly in complex soft-tissue surgeries.

Under the proposed association, the focus will be on expanding access to robot-assisted minimally invasive surgeries by deploying high-precision and stability-driven surgical robotic platforms.

A key element of the collaboration is the integration of artificial intelligence with digital surgery workflows, which is expected to support more consistent procedural pathways, improve clinical efficiency and reduce variability in surgical outcomes.

The initiative also seeks to strengthen healthcare infrastructure in the region through technology transfer, clinician training programmes and scalable deployment models for medical robotics.

Borns Medical Robotics, described as a globally recognised player in surgical medical robotics, will contribute its expertise in robotic surgical platforms and AI-enabled technologies.

Shukra Pharmaceuticals, in turn, will leverage its regulatory execution capabilities, established healthcare market presence and distribution reach across India and South Asia to support adoption and commercialisation.

The MoU is non-binding in nature and reflects the intent of both parties to explore definitive agreements in the future, subject to detailed commercial terms, regulatory clearances and mutual consent.

Stay tuned for more such updates on Digital Health News